ReviewPharmaceutics2021
Functionalized Lanthanide Oxide Nanoparticles for Tumor Targeting, Medical Imaging, and Therapy.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate.Scientific reports · 2026Article
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- High Quantum Yields and Biomedical Fluorescent Imaging Applications of Photosensitized Trivalent Lanthanide Ion-Based Nanoparticles.International journal of molecular sciences · 2024Review
- Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Targeted Nanotheransotics: Integration of Preclinical MRI and CT in the Molecular Imaging and Therapy of Advanced Diseases.Nanotheranostics · 2024Review
- Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier.Oncology research · 2024Review
- Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents.Pharmaceutics · 2023Review
- Magnetic Nanoparticles for Therapy and Diagnosis in Nanomedicine.Pharmaceutics · 2023Article
- Recent advances of lanthanide nanomaterials in Tumor NIR fluorescence detection and treatment.Materials today. Bio · 2023Review
- Modulating the Surface Properties of Lithium Niobate Nanoparticles by Multifunctional Coatings Using Water-in-Oil Microemulsions.Nanomaterials (Basel, Switzerland) · 2023Article
- Dosimetry Effects Due to the Presence of Fe Nanoparticles for Potential Combination of Hyperthermic Cancer Treatment with MRI-Based Image-Guided Radiotherapy.International journal of molecular sciences · 2022Article
- Special Issue "Advanced Nanomaterials for Bioimaging".Nanomaterials (Basel, Switzerland) · 2022Article
- Mono and Multiple Tumor-Targeting Ligand-Coated Ultrasmall Gadolinium Oxide Nanoparticles: Enhanced Tumor Imaging and Blood Circulation.Pharmaceutics · 2022Article
- Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaFPharmaceutics · 2022Article
- Enhanced Tumor Imaging Using Glucosamine-Conjugated Polyacrylic Acid-Coated Ultrasmall Gadolinium Oxide Nanoparticles in Magnetic Resonance Imaging.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Recent progress in functionalized lanthanide oxide (Ln
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.